Pharmaceuticalcare services and results in project ImPACT: Hyperlipidemia

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

Volumn 40, Issue 2, 2000, Pages 157-165

  Bluml, Benjamin M ^a   McKenney, James M ^b   Cziraky, Mark J ^c  

^a APhA Foundation   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c HEALTHCORE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ARTICLE; BLOOD; FEMALE; HEALTH EDUCATION; HOSPITAL INFORMATION SYSTEM; HUMAN; HYPERLIPIDEMIA; MALE; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PHARMACY; PUBLIC RELATIONS; QUALITY CONTROL; TREATMENT OUTCOME; UNITED STATES;

ANTILIPEMIC AGENTS; CHOLESTEROL; COMMUNITY PHARMACY SERVICES; FEMALE; HEALTH EDUCATION; HUMANS; HYPERLIPIDEMIAS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; POINT-OF-CARE SYSTEMS; QUALITY CONTROL; UNITED STATES;

EID: 0034154584     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1086-5802(16)31059-2     Document Type: Article

References (21)

1. American Heart Association 2000 Heart and Stroke Statistical Update 1999 American Heart Association Dallas, Tex
2. W.P. Castelli Lipoprotein and cardiovascular disease: biological basis and epidemiological studies Paper presented at: Association for Pharmacoeconomics and Outcomes Research Lipid Conference; November 1997 Orlando, Fla
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II) JAMA 269 1993 3015 3023
4. M. Frick M.O. Elo K. Haapa Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med. 317 1987 1237 1245
5. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results, I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
6. F.M. Sacks M.A. Pfeffer L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med. 335 1996 1001 1009
7. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 344 1994 1383 1389
8. J. Shepherd S.M. Cobbe I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med. 333 1995 1301 1307
9. J.R. Downs M. Clearfield S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA. 279 1998 1615 1622
10. S.L. Konzem D.R. Gray M.L. Kashyap Effect of pharmaceutical care on optimal colestipol treatment in elderly hypercholesterolemic veterans Pharmacotherapy. 17 1997 576 583
11. J.M. McKenney J.S. Slining H.R. Henderson The effect of clinical pharmacy services on patients with essential hypertension Circulation. 48 1973 1104 1111
12. G. Schectman N. Wolff J.C. Byrd Physician extenders for cost-effective management of hypercholesterolemia J Gen Intern Med. 11 1996 277 286
13. Health Employer Data Information Set measures [draft] May 1998 National Committee for Quality Assurance Reston, Va
14. Clinical Laboratory Improvement Amendments (CLIA '88) 1988 P Law No. 100-578, October 31
15. T.J. Hoerger M.V. Vala J.W. Bray Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible US adults Am J Cardiol. 82 1998 61 65
16. J. Avorn J. Monette A. Lacour Poor compliance with lipid-lowering medications JAMA. 279 1998 1458 1462
17. L.A. Simons G. Levis J. Simons Apparent discontinuation rates in patients prescribed lipid-lowering drugs Med J Austral. 164 4 1996 208 211
18. S.E. Andrade A.M. Walker L.K. Gottlieb Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 332 1995 1125 1131
19. M. Eriksson K. Hadell I. Holme Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care J Intern Med. 243 1998 373 380
20. J.J. Marcelino K.R. Feingold Inadequate treatment with HMG-CoA reductase inhibitors by health care providers Am J Med. 100 1996 605 610
21. T.A. Pearson I.M. Laurora Treatment success in patient subgroups in the lipid treatment assessment project (L-TAP) Circulation 96 1998 Abstract 361